Clinical Trial

the Safety and Efficacy Evaluation of HGI-002 Injection in Patients With Transfusion-Dependent α-Thalassemia

Name: the Safety and Efficacy Evaluation of HGI-002 Injection in Patients With Transfusion-Dependent α-Thalassemia — clinical trial record (NCT05851105)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Early Phase 1

View on ClinicalTrials.gov →

Summary

This is an open label study to evaluate the safety and efficacy of α-globin Restored Autologous Hematopoietic Stem Cells in α-Thalassemia Major Patients

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2023-05-06.

Trial Details

NCT Number	NCT05851105
Lead Sponsor	Shenzhen Hemogen
Conditions	α-thalassemia
Enrollment	3 participants
Start Date	2022-10-08
Primary Completion	2026-12-30 (estimated)
Study Completion	2026-12-30 (estimated)
Updated on ClinicalTrials.gov	2024-11-29